CellProthera will tech transfer to CELLforCURE by SEQENS this year, with plans to produce clinical batches starting in 2026.

CellProthera says it chose CELLforCURE by SEQENS as its CDMO for the quality of its infrastructure, equipment, and expertise of its team.

Recombinant zoster vaccine reduces all-cause mortality in patients with immune-mediated inflammatory diseases receiving Janus ...

Specifically, rates of falls, fractures, glaucoma, and cognitive changes were comparable across both timing strategies. The ...

Under-desk treadmills are a great way to increase your step count. We found 7 under desk treadmill deals that are ...

Three-dimensional printing is transforming medical care, letting the health care field shift from mass-produced solutions to customized treatments tailored to each patient’s needs. For instance, ...

Despite the 2020 catastrophe, a slew of dam safety fixes remain shelved. “We’re still at the starting blocks waiting for the ...

Our premium News+ ad-free experience – only $10 more every 4 weeks!

Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a ...

KORKOR “Whatever you do, work at it with all your heart, as working for the Lord, not for human masters, since you know that ...

For centuries, the default subject in medicine research and training has been the male. Julia Robinson talks to the ...

Together, they form an ancient marketing playbook that still makes sense today. Aristotle’s ancient rhetoric is wildly ...